Literature DB >> 33440682

Characterization of Yersinia pestis Phage Lytic Activity in Human Whole Blood for the Selection of Efficient Therapeutic Phages.

Sarit Moses1, Yaron Vagima1, Avital Tidhar1, Moshe Aftalion1, Emanuelle Mamroud1, Shahar Rotem1, Ida Steinberger-Levy1.   

Abstract

The global increase in multidrug-resistant (MDR) pathogenic bacteria has led to growing interest in bacteriophage ("phage") therapy. Therapeutic phages are usually selected based on their ability to infect and lyse target bacteria, using in vitro assays. In these assays, phage infection is determined using target bacteria grown in standard commercial rich media, while evaluation of the actual therapeutic activity requires the presence of human blood. In the present work, we characterized the ability of two different Yersinia pestis lytic phages (ϕA1122 and PST) to infect and kill a luminescent Y. pestis EV76 strain suspended in Brain Heart Infusion (BHI)-rich medium or in human whole blood, simulating the host environment. We found that the ability of the phages to infect and lyse blood-suspended Y. pestis was not correlated with their ability to infect and lyse BHI-suspended bacteria. While the two different phages exhibited efficient infective capacity in a BHI-suspended culture, only the PST phage showed efficient lysis ability against blood-suspended bacteria. Therefore, we recommend that for personalized phage therapy, selection of phage(s) for efficient treatment of patients suffering from MDR bacterial infections should include prior testing of the candidate phage(s) for their lysis ability in the presence of human blood.

Entities:  

Keywords:  Yersinia pestis; bacteriophage; human whole blood; personalized phage therapy; phage selection

Mesh:

Year:  2021        PMID: 33440682      PMCID: PMC7827537          DOI: 10.3390/v13010089

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  36 in total

Review 1.  Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.

Authors:  Kaitlyn E Kortright; Benjamin K Chan; Jonathan L Koff; Paul E Turner
Journal:  Cell Host Microbe       Date:  2019-02-13       Impact factor: 21.023

2.  Phage therapy's latest makeover.

Authors:  Charles Schmidt
Journal:  Nat Biotechnol       Date:  2019-06       Impact factor: 54.908

Review 3.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

4.  Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model.

Authors:  Taruna Anand; Nitin Virmani; Sudarshan Kumar; Ashok Kumar Mohanty; S Pavulraj; Bidhan Ch Bera; Rajesh K Vaid; Umang Ahlawat; B N Tripathi
Journal:  J Glob Antimicrob Resist       Date:  2019-10-08       Impact factor: 4.035

Review 5.  Pneumonic Plague: The Darker Side of Yersinia pestis.

Authors:  Roger D Pechous; Vijay Sivaraman; Nikolas M Stasulli; William E Goldman
Journal:  Trends Microbiol       Date:  2015-12-14       Impact factor: 17.079

6.  A brief history of the antibiotic era: lessons learned and challenges for the future.

Authors:  Rustam I Aminov
Journal:  Front Microbiol       Date:  2010-12-08       Impact factor: 5.640

7.  Multiple antimicrobial resistance in plague: an emerging public health risk.

Authors:  Timothy J Welch; W Florian Fricke; Patrick F McDermott; David G White; Marie-Laure Rosso; David A Rasko; Mark K Mammel; Mark Eppinger; M J Rosovitz; David Wagner; Lila Rahalison; J Eugene Leclerc; Jeffrey M Hinshaw; Luther E Lindler; Thomas A Cebula; Elisabeth Carniel; Jacques Ravel
Journal:  PLoS One       Date:  2007-03-21       Impact factor: 3.240

8.  A Rapid Molecular Test for Determining Yersinia pestis Susceptibility to Ciprofloxacin by the Quantification of Differentially Expressed Marker Genes.

Authors:  Ida Steinberger-Levy; Ohad Shifman; Anat Zvi; Naomi Ariel; Adi Beth-Din; Ofir Israeli; David Gur; Moshe Aftalion; Sharon Maoz; Raphael Ber
Journal:  Front Microbiol       Date:  2016-05-19       Impact factor: 5.640

9.  Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report.

Authors:  Serge Jennes; Maia Merabishvili; Patrick Soentjens; Kim Win Pang; Thomas Rose; Elkana Keersebilck; Olivier Soete; Pierre-Michel François; Simona Teodorescu; Gunther Verween; Gilbert Verbeken; Daniel De Vos; Jean-Paul Pirnay
Journal:  Crit Care       Date:  2017-06-04       Impact factor: 9.097

Review 10.  Phage therapy for severe bacterial infections: a narrative review.

Authors:  Aleksandra Petrovic Fabijan; Ali Khalid; Susan Maddocks; Josephine Ho; Timothy Gilbey; Indy Sandaradura; Ruby Cy Lin; Nouri Ben Zakour; Carola Venturini; Bethany Bowring; Jonathan R Iredell
Journal:  Med J Aust       Date:  2019-10-06       Impact factor: 12.776

View more
  5 in total

Review 1.  Phage Therapy in Israel, Past, Present, and Future.

Authors:  Amit Rimon; Daniel Gelman; Ortal Yerushalmy; Shunit Coppenhagen-Glazer; Eyal Katvan; Ran Nir-Paz; Ronen Hazan
Journal:  Phage (New Rochelle)       Date:  2022-06-16

2.  An Improvement in Diagnostic Blood Culture Conditions Allows for the Rapid Detection and Isolation of the Slow Growing Pathogen Yersinia pestis.

Authors:  Efi Makdasi; Yafit Atiya-Nasagi; David Gur; Ayelet Zauberman; Ofir Schuster; Itai Glinert; Shlomo Shmaya; Elad Milrot; Haim Levy; Shay Weiss; Theodor Chitlaru; Emanuelle Mamroud; Orly Laskar
Journal:  Pathogens       Date:  2022-02-16

3.  Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague.

Authors:  Yaron Vagima; David Gur; Moshe Aftalion; Sarit Moses; Yinon Levy; Arik Makovitzki; Tzvi Holtzman; Ziv Oren; Yaniv Segula; Ella Fatelevich; Avital Tidhar; Ayelet Zauberman; Shahar Rotem; Emanuelle Mamroud; Ida Steinberger-Levy
Journal:  Viruses       Date:  2022-03-26       Impact factor: 5.818

4.  Phage Resistance Accompanies Reduced Fitness of Uropathogenic Escherichia coli in the Urinary Environment.

Authors:  Jacob J Zulk; Justin R Clark; Samantha Ottinger; Mallory B Ballard; Marlyd E Mejia; Vicki Mercado-Evans; Emmaline R Heckmann; Belkys C Sanchez; Barbara W Trautner; Anthony W Maresso; Kathryn A Patras
Journal:  mSphere       Date:  2022-08-03       Impact factor: 5.029

5.  Reporter-Phage-Based Detection and Antibiotic Susceptibility Testing of Yersinia pestis for a Rapid Plague Outbreak Response.

Authors:  Sarit Moses; Moshe Aftalion; Emanuelle Mamroud; Shahar Rotem; Ida Steinberger-Levy
Journal:  Microorganisms       Date:  2021-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.